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Abstract
Background: Kenya introduced the monovalent G1P [8] Rotarix® vaccine into the infant immunization schedule in
July 2014. We examined trends in rotavirus group A (RVA) genotype distribution pre- (January 2010–June 2014) and
post- (July 2014–December 2018) RVA vaccine introduction.
Methods: Stool samples were collected from children aged < 13 years from four surveillance sites across Kenya:
Kilifi County Hospital, Tabitha Clinic Nairobi, Lwak Mission Hospital, and Siaya County Referral Hospital (children
aged < 5 years only). Samples were screened for RVA using enzyme linked immunosorbent assay (ELISA) and VP7
and VP4 genes sequenced to infer genotypes.
Results: We genotyped 614 samples in pre-vaccine and 261 in post-vaccine introduction periods. During the pre-
vaccine introduction period, the most frequent RVA genotypes were G1P [8] (45.8%), G8P [4] (15.8%), G9P [8]
(13.2%), G2P [4] (7.0%) and G3P [6] (3.1%). In the post-vaccine introduction period, the most frequent genotypes
were G1P [8] (52.1%), G2P [4] (20.7%) and G3P [8] (16.1%). Predominant genotypes varied by year and site in both
pre and post-vaccine periods. Temporal genotype patterns showed an increase in prevalence of vaccine heterotypic
genotypes, such as the commonly DS-1-like G2P [4] (7.0 to 20.7%, P < .001) and G3P [8] (1.3 to 16.1%, P < .001)
genotypes in the post-vaccine introduction period. Additionally, we observed a decline in prevalence of genotypes
G8P [4] (15.8 to 0.4%, P < .001) and G9P [8] (13.2 to 5.4%, P < .001) in the post-vaccine introduction period.
Phylogenetic analysis of genotype G1P [8], revealed circulation of strains of lineages G1-I, G1-II and P [8]-1, P [8]-III
and P [8]-IV. Considerable genetic diversity was observed between the pre and post-vaccine strains, evidenced by
distinct clusters.
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Conclusion: Genotype prevalence varied from before to after vaccine introduction. Such observations emphasize
the need for long-term surveillance to monitor vaccine impact. These changes may represent natural secular
variation or possible immuno-epidemiological changes arising from the introduction of the vaccine. Full genome
sequencing could provide insights into post-vaccine evolutionary pressures and antigenic diversity.
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Background
Childhood diarrhea caused by rotavirus group A (RVA)
infection remains a leading cause of morbidity and mor-
tality in young children globally [1]. In 2016, RVA infec-
tions were estimated to be responsible for 1,537,000
hospitalization cases, 128,500 deaths globally and over
80% of these deaths occurred in developing countries
[2]. In Kenya alone, it is estimated that rotavirus infec-
tion accounts for over 3000 deaths annually in children
under 5 years of age [3].
Upon infection by the virus, immune response to RVA
by the host is directed to the highly variable VP7 and
VP4 genes found on two separate segments of the
double-stranded RNA genome [4]. RVA G and P geno-
types exist as multiple variants in nature, few of which
have been found to infect humans [4]. Up to 36 G and
51 P genotypes have been detected globally in both
humans and animals, with multiple G-P combinations
[5]. Molecular studies have characterized circulating ge-
notypes worldwide with predominance of genotypes
G1P [8], G2P [4], G3P [8], G4P [8], G9P [8] and G12P
[8] (in decreasing order of prevalence) [6, 7]. Although
the distribution of these genotypes varies from region to
region and from one season to another, genotype G1P
[8] has remained the most dominant genotype globally
[6]. In Africa, there is a high diversity of genotypes, most
commonly G1P [8], G2P [4], G9P [8], G2P [6], G12P [8]
and G3P [6], with G1P [8] and G2P [4] predominant [7,
8]. Significant RVA infections are also caused by strains
of uncommon genotypes including G1P [4], G2P [8],
G9P [4], G12P [4], G8P [6], G8P [8] and G12P [6] [7, 8].
Such uncommon strains also show a wide variation from
one region to the other, and can spread globally to be-
come common strains. For instance, genotypes G9P [8]
and G12P [8] emerged and contributed to a larger pro-
portion of global RVA infections [9]. An understanding
of these genetic diversity after vaccine introduction is
necessary for design and implementation of effective
control programs.
In 2009, the World Health Organization (WHO) rec-
ommended the inclusion of RotaTeq® (Merck Vaccines,
Whitehouse Station, New Jersey) or Rotarix® (GlaxoS-
mithKline Biologicals, Rixensart, Belgium) vaccines in
the national immunization programs of countries that
experience high diarrhea morbidity and mortality burden
due to RVA disease [10]. The introduction and increased
use of these vaccines have reduced up to 76% of rotavirus
hospitalizations in children < 5 years [11] and averted up to
28,800 deaths globally, including 84% of the deaths in sub-
Saharan Africa [2]. Furthermore, these vaccines showed
overall good clinical protection against multiple homotypic
and heterotypic RVA strains in humans [12]. Kenya incor-
porated the monovalent G1P [8] Rotarix® vaccine into the
national immunization program in July 2014, administered
in two oral doses offered at weeks 6 and 10 of age. The
Rotavirus Immunization Programme Evaluation in Kenya
(RIPEK) was established as a collaboration among existing
rotavirus surveillance platforms across Kenya to monitor
the impact of Rotarix vaccine introduction against rotavirus
disease and circulating RVA genotypes. Substantial effect-
iveness of the vaccine in Kenya (vaccine coverage of 72%
[13]) and the entire sub-Saharan region (where disease bur-
den is high) has been recorded, and the decline in incidence
of all-cause and rotavirus associated diarrhea admissions
has been attributed to vaccine implementation [14–18].
However, there are limited data on RVA diversity in post-
vaccine introduction periods in this region. The current re-
port describes the distribution and temporal patterns of
RVA genotypes observed before and after Rotarix vaccine
introduction in Kenya.
Methods
Rotavirus surveillance
RVA surveillance was carried out in four health facilities
in coastal, western and central regions of Kenya. These
surveillance sites were: Kilifi County Hospital (KCH) in
Kilifi County, Tabitha Clinic (TC), in Kibera, Nairobi
County, Saint Elizabeth Lwak Mission Hospital (LMH)
and Siaya County Referral Hospital (SCRH) in Siaya
County (Supplementary Figure 1). KCH is a government
hospital located on the Kenyan coast serving a rural and
semi-rural population. Rotavirus surveillance at KCH
started in September 2009, and is implemented by
KEMRI Wellcome Trust Research Program (KWTRP) a
partnership between Kenya Medical Research Institute
and Wellcome Trust, UK [19, 20]. SCRH is a govern-
ment hospital which also serves a rural and semi-rural
population in Siaya County, Western Kenya. SCRH has
had an active rotavirus surveillance since 2010 and is im-
plemented by KEMRI Center for Global Health
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Research, KEMRI-CGHR in collaboration with US Cen-
ters for Disease Control and Prevention (CDC) [21].
LMH is a private health facility serving a rural popula-
tion in Asembo, Siaya County where rotavirus surveil-
lance is carried out as part of the Population Based
Infectious Disease Surveillance (PBIDS) platform under
KEMRI-CGHR and CDC [22]. PBIDS also supports rota-
virus surveillance at Tabitha Clinic, a private health facil-
ity in Kibera, Nairobi County.
Surveillance was conducted during January 2010 – De-
cember 2018 for all the sites except for SCRH where
surveillance ended in December 2016. Stool samples
were collected from children aged < 13 years (in KCH,
TC, LMH) and < 5 years (in SCRH) of age presenting
with acute gastroenteritis (AGE). AGE was defined as ≥3
watery stools passed within a 24-h period during the ill-
ness for KCH, TC and LMH, while for SCRH, AGE was
defined as ≥3 loose stools and/or ≥ 1 episode of unex-
plained vomiting followed by loose stool within a 24-h
period beginning no more than 7 days before the visit to
SCRH.
Laboratory processing
RVA was tested by use of commercially available enzyme
immunoassays. The ProSpecT™ Rotavirus Kit (Oxoid,
Basingstoke UK) was used to test samples collected from
KCH while the Rotaclone® kit (Premier™ Meridian Bio-
science, Cincinnati, Ohio, USA) was used to test samples
collected from LMH, SCRH, and TC. For samples col-
lected from LMH, KCH and TC, partial fragments of the
segments encoding the outer capsid proteins, VP4 (660
bp) and VP7 (881 bp), were amplified in a One-step Re-
verse Transcriptase Polymerase Chain Reaction (RT-
PCR) using previously described primer pairs [23, 24].
Successful amplification was visualized by electrophor-
esis of the PCR product in a 2% agarose gel. PCR prod-
ucts of confirmed positives were purified using GFX
DNA purification kit (GFX-Amersham, Amersham, UK),
according to the manufacturer’s instructions. Confirmed
positives were then sequenced using Big Dye Terminator
3.1 (Applied Biosystems, Foster City, California, USA)
with the same primers as in PCR amplification on an
ABI Prism 3130xl Genetic Analyzer (Applied Biosys-
tems, Foster City, California, USA).
RVA genotyping
Reads from the sequencer were trimmed (removing re-
gions including primer sequences) and assembled into
contigs (consensus sequence formed from aligning the
forward and reverse reads) using Sequencher version
5.4.6 (Gene Codes Corp Inc., Ann Arbor, MI, USA). The
cleaned sequences for the VP7 and VP4 genes have been
deposited to GenBank database: https://www.ncbi.nlm.
nih.gov/genbank/. Sequence accession numbers for these
genes are provided in supplementary Table 2 and sup-
plementary Table 3, respectively. G and P genotypes
were determined by submitting cleaned sequences to the
online automated Virus Pathogen Resource genotyping
tool [25]. Using this method only a single genotype per
specimen was identified. However, 8.6% (n = 113) of the
samples were typed for only one of the genes due to fail-
ure in sequencing and/or contig assembly, supplemen-
tary Table 1, and were excluded from the main analysis.
For positive samples collected from SCRH, sample pro-
cessing and genotyping was performed as previously de-
scribed [26]. Briefly, full length VP7 gene (1062 bp) was
amplified using sBeg9 and End9 primers. The resulting
cDNA was used for G typing using primers End9,
aAT8v, aBT1, aCT2, aDT4, mG3, mG9, mG10 and G12
for G1, G2, G3, G4, G8, G9, G10 and G12 genotypes, re-
spectively [27, 28]. Alternatively, partial-length amplifi-
cation of the VP4 gene (876 bp) was achieved by use of
Con2 and Con3 primers. P typing was performed using
a mixture of primers consisting of Con3 and primers 1
T-1, 2 T-1, 3 T-1, 4 T-1, 5 T-1, mP [11] and P [14] for
genotypes P [8], P [4], P [6], P [9], P [10], P [11] and P
[14], respectively [23, 29]. In this instance, untypable G
(8.9%, n = 15/168) and P (22.6%, n = 38/168) genotypes
and mixed infections (18.5%, n = 31/168) were observed
and subsequently excluded from analysis.
Phylogenetic analysis of the Kenyan G1 and P [8] vaccine
strains
Maximum likelihood (ML) method was used to deter-
mine the phylogenetic relationship of the partial se-
quences of genotypes G1 and P [8] observed during the
pre- and post-vaccine periods in Kenya, and further
compared to RVA strains circulating globally. Global
contemporaneous sequences were retrieved from Gen-
Bank (as of May 2020) and compared to local strains.
Sequences were aligned using MAFFT v7.2 [30] and vi-
sualized in AliView v1.8 [31]. Best-fit volutionary models
were tested and selected in IQTREE v1.6 [32] using the
Bayesian Information Criteria [33]. ML trees were in-
ferred using IQTREE with 1000 bootstrap replicates.
The resulting trees were visualized and edited in FigTree
v1.4.3 (http://tree.bio.ed.ac.uk/software/figtree/). Nucleo-
tide distances matrixes were prepared using the p-
distance algorithm inferred in MEGA v10 [34]. The trees
were drawn to scale indicating nucleotide substitutions
rates per site.
Data analysis
Data collating and analyses were performed in Microsoft
Excel and R version 3.5. Genotype data collected from
LMH and SCRH were merged to constitute data from
Siaya County. The summary of proportions was con-
ducted for each genotype by site and period of detection.
Mwanga et al. BMC Infectious Diseases          (2020) 20:504 Page 3 of 12
Frequency distribution and temporal pattern graphs
were generated. Two-sided proportional tests of the
most common genotypes during the pre-vaccine (Janu-
ary 2010 thru June 2014) and post-vaccine (July 2014
thru December 2018) eras were performed in R, and P-
values < 0.05 were considered statistically significant.
Results
A total of 6562 stool samples were collected from health
facilities in LMH, SCRH, TC and KCH. Of the 1312
(20.0%) RVA positive samples, individual G and P geno-
types were identified in 928 (70.7%) and 904 (68.9%)
samples, respectively, while 875 (66.7%) samples were
successfully genotyped for both G and P genes [LMH
(n = 38), SCRH (n = 161), TC (n = 84), and KCH (n =
592)]. Of these, 614 (70.2%) were observed in the pre-
vaccine (January 2010 – June 2014) and 261 (29.8%) in
the post-vaccine (July-2014 – December 2018) introduc-
tion periods, respectively.
G and P genotypes circulating in Kenya
Overall, nine different G types (G1, G2, G3,G4, G8, G9,
G10, G12, G29) and four P types (P [4], P [6], P [8] and
P [14]) were observed in Kenya. The most common G
type was G1 (49.5%) followed by G9 (12.7%), G8 (12.0%),
G2 (11.1%) and G3 (10.1%), Table 1. Genotypes G4,
G10, G12 and G29 were detected at low frequencies (< 4%).
The most common P types were P [8] (68.4%) and P [4]
(23.6%), while P [6] (7.7%) and the less common P [14]
(0.3%) were also observed, Table 1.
Rotavirus genotype distribution in pre- and post-
vaccination eras
In the entire period, 22 different G/P combinations were
identified, Table 2. G1P [8] (47.7%) was the most com-
mon genotype followed by G8P [4] (11.2%), G2P [4]
(11.1%), G9P [8] (10.9%), G3P [8] (5.7%) and G3P [6]
(2.9%). In addition to these common genotypes, multiple
other rare genotypes; G1P [4], G1P [6], G1P [14], G2P
[8], G3P [4], G3P [6], G4P [4], G8P [6], G8P [14], G9P
[6], G9P [14], G10P [8], G12P [4], G12P [6], G12P [8]
were observed in low frequency (< 2%), Table 2.
Figure 1 a, b, c and d show the temporal distribution
of RVA genotypes in Kilifi, Siaya (i.e, pooled SCRH and
LMH data) and Nairobi counties, and Kenya (pooled
countrywide), respectively. Genotypes G1P [8], G2P [4],
G8P [4], G3P [6], G3P [8] and G9P [8] were observed
across all three sites. G1P [8] was observed in all peri-
odss, in all sites, except in 2011 and 2016 in Nairobi. In
contrast, genotypes G2P [4], G3P [8], G3P [6], G8P [4]
and G9P [8] showed a fluctuating pattern in all three
sites. Notably, genotype G2P [4] was observed in pre-
and post-vaccine periods in Kilifi and Nairobi, and only
in the post- vaccine period in Siaya. Furthermore, geno-
type G3P [8] was observed in Kilifi and Nairobi counties
in pre- and post-vaccine periods and only in pre-vaccine
period in Siaya, while genotype G3P [6] was detected in
all three sites, although in moderate proportions. Add-
itionally, genotype G9P [8] was observed in pre- and
post- vaccine periods in Kilifi, unlike in Nairobi and
Siaya where it was only observed in the pre-vaccine
period. Genotype G8P [4] occurred in pre- and post-
vaccine periods in Nairobi county and only in the pre-
vaccine period in Kilifi and Siaya counties.
During the period before vaccine introduction in
Kenya, G1P [8] (45.8%) was the predominant genotype
observed in this population, followed by G8P [4]
(15.8%), G9P [8](13.2%), G2P [4] (7.0%) and G3P [6]
(3.1%). After vaccine introduction, G1P [8] remained the
dominant genotype (52.1%), followed by G2P [4]
(20.7%), G3P [8] (16.1%), G9P [8] (5.4%) and G3P [6]
(2.7%). Multiple other genotypes were also observed in
pre- and post-vaccine periods, although in low propor-
tions (< 2%), Tables 2, 3.
Overall, at these surveillance sites, the first four RVA
periods, saw an alternating pattern of dominance be-
tween G8P [4] and G1P [8] (Fig. 1d). G8P [4] was the
predominant genotype in 2010 (54/153; 35.3%) and in
2012 (42/150;28.0%), while G1P [8] predominated in
2011 (117/160;73.1%) and 2013 (60/104;57.7%) through
to 2014 (vaccine introduction periods) breaking the cyc-
lic pattern. During this periods, G2P [4] and G9P [8] cir-
culated in moderate proportions (1–20%) and (2–14%),
respectively (Table 2). After vaccine introduction, G1P
[8] dominated immediately in the first year of vaccine
introduction (2015) (91/101, 90.1%). This phenomena
was however, short lived and there was a re-emergence
of G2P [4] (35/44; 79.5%) in the second year of vaccine
period (2016), which was among the common genotypes
in 2017 together with genotype G1P [8](7/16;43.6%).
Table 1 Frequency of RVA G and P genotype circulation in
Kenya between 2010 and 2018
G Genotypes n % P Genotypes n %
G1 459 49.5 P [4] 213 23.6
G2 103 11.1 P [6] 70 7.7
G3 94 10.1 P [8] 618 68.4
G4 1 0.1 P [14] 3 0.3
G8 111 12.0
G9 118 12.7
G10 5 0.5
G12 36 3.9
G29 1 0.1
Total 928 Total 904
The table represents number of samples where only one genotype was
observed. Proportion of specimen observed as mixed infections is indicated
under section 2.3
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G3P [8] (41/66;62.1%) dominated in the fourth year post-
vaccine introduction period (2018), whereas G1P [8] (17/
66;25.8%) and G2P [4] (4/66;6.1%) continuously circulated,
although in reduced proportions. Notably, a separate ana-
lysis of the post-vaccine G3P [8] (data not shown), re-
vealed that 4.8% (n = 2/41) were of the equine-like
genotype while the rest were wild-type genotype.
In the post-vaccine introduction period, relative to the
pre-vaccine period, we observed a significant increase in
prevalence of genotypes G2P [4] (7.0% vs. 20.7%, P < .001)
and G3P [8] (1.3% vs. 16.1%, P < .001) and significant de-
cline in prevalence of genotypes G8P [4] (15.8% vs. 0.4%,
P < .001) and G9P [8] (13.2% vs. 5.4%, P < .001), Fig. 2. No
significant difference in the prevalence of the vaccine geno-
type G1P [8] (45.8 vs. 52.1%,P = .35) was measured before
and after vaccine introduction. A decline in genotype diver-
sity was observed after vaccine introduction (11 genotypes)
as compared to pre-vaccine period (21 genotypes).
Phylogenetic analysis of the Kenya G1 and P [8] vaccine
strains
As shown in Fig. 3a, phylogenetic analysis of Kenyan
G1 strains revealed circulation of lineages G1-I and
G1-II with representative sequences from all the three
sites (Kilifi, Kibera and Lwak). In both pre and post-
vaccine periods, detected strains were predominantly
found within lineage G1-I with a few within lineage
G1-II. Interestingly, within lineage G1-I, pre and post
vaccine strains formed separate clusters. However,
three post-vaccine strains (2015; n = 2, 2014; n = 1)
clustered within pre-vaccine strains, which showed
high nucleotide sequence identities of up to 99% to
pre-vaccine strains. Additionally, a single pre-vaccine
strain, observed in 2014, grouped within the post-
vaccine cluster, which showed high nucleotide iden-
tities of up to 100% to other post-vaccine strains. The
lineage G1-I strains also clustered with other strains
isolated from Kenya (2009), Malawi (2012), Togo
(2011), Russia (2013), India (2013), Kuwait (2016),
USA (2011) and Italy (2015), with high nucleotide
identities ranging between 98 and 99%. Lineage II
cluster contained strains observed in pre-vaccine
period (n = 14) which clustered with other globally
isolated strains from Pakistan (2013), India (2012),
USA (2013) and Hungary (2012), with nucleotide
identities of up to 99%. In contrast, a single post-
Table 2 Temporal distribution of RVA GP genotypes observed in Kenya between 2010 and 2018
2010 2011 2012 2013 2014 2015 2016 2017 2018 Total
Genotype n % n % n % n % n % n % n % n % n % n %
G1P [8] 40 26.1 117 73.1 39 26 60 57.7 38 46.9 91 90.1 8 18.2 7 43.8 17 25.8 417 47.7
G8P [4] 54 35.3 0 0 42 28 1 1 0 0 0 0 0 0 1 6.3 0 0 98 11.2
G2P [4] 11 7.2 1 0.6 19 12.7 5 4.8 14 17.3 3 3 35 79.5 5 31.3 4 6.1 97 11.1
G9P [8] 18 11.8 20 12.5 30 20 8 7.7 17 21 1 1 0 0 0 0 1 1.5 95 10.9
G3P [8] 0 0 0 0 0 0 4 3.8 4 4.9 0 0 0 0 1 6.3 41 62.1 50 5.7
G3P [6] 2 1.3 0 0 2 1.3 13 12.5 2 2.5 4 4 0 0 2 12.5 0 0 25 2.9
G12P [6] 2 1.3 5 3.1 4 2.7 1 1 1 1.2 0 0 0 0 0 0 1 1.5 14 1.6
G1P [6] 1 0.7 1 0.6 2 1.3 9 8.7 0 0 0 0 0 0 0 0 0 0 13 1.5
G12P [8] 2 1.3 6 3.8 1 0.7 0 0 0 0 1 1 0 0 0 0 1 1.5 11 1.3
G9P [6] 8 5.2 1 0.6 1 0.7 0 0 1 1.2 0 0 0 0 0 0 0 0 11 1.3
G1P [4] 5 3.3 1 0.6 2 1.3 0 0 0 0 1 1 0 0 0 0 0 0 9 1
G9P [4] 4 2.6 2 1.3 1 0.7 0 0 0 0 0 0 0 0 0 0 0 0 7 0.8
G10P [8] 0 0 4 2.5 0 0 1 1 1 1.2 0 0 0 0 0 0 0 0 6 0.7
G8P [8] 1 0.7 1 0.6 3 2 0 0 0 0 0 0 0 0 0 0 0 0 5 0.6
G8P [6] 1 0.7 0 0 3 2 0 0 0 0 0 0 0 0 0 0 0 0 4 0.5
G2P [8] 1 0.7 0 0 0 0 1 1 1 1.2 0 0 0 0 0 0 1 1.5 4 0.5
G12P [4] 2 1.3 1 0.6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0.3
G3P [4] 0 0 0 0 0 0 0 0 2 2.5 0 0 0 0 0 0 0 0 2 0.2
G4P [4] 0 0 0 0 0 0 0 0 0 0 0 0 1 2.3 0 0 0 0 1 0.1
G1P [14] 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 0.1
G9P [14] 0 0 0 0 1 0.7 0 0 0 0 0 0 0 0 0 0 0 0 1 0.1
G8P [14] 1 0.7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0.1
Total 153 160 150 104 81 101 44 16 66 875
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vaccine strain, isolated in Kibera (KBR337), was ob-
served within lineage G1-II cluster, which showed
high nucleotide and amino acid identity of up to
100% to the Rotarix vaccine and other vaccine-
derived strains from Japan, Brazil and Korea.
As shown in Fig. 3b, analysis of the Kenyan P [8]
genotype revealed groupings into lineage P [8]-III (pre-
dominant lineage) with a few others belonging in lineage
P [8]-I and P [8]-IV. Within lineage P [8]-III, distinct
clusters of pre and post-vaccine strains were evident
Fig. 1 Temporal rotavirus genotype distribution in the three surveillance sites across Kenya; a Kilifi County Hospital in Kilifi County, b Tabitha
Clinic in Kibera, Nairobi County, c Siaya County (combined genotype data from Lwak Mission Hospital and Siaya Referral Hospital) and d
combination of the three Counties in Kenya between 2010 to 2018
Table 3 Frequency of RVA genotypes detected in Kenya in pre-vaccine (2010 - June 2014) and post-vaccine (July 2014–2018)
Pre-vaccine (2010-June 2014) Post-vaccine (July 2014–2018)
P [4] P [6] P [8] P [14] Total P [4] P [6] P [8] Total
G1 8 13 281 1 303 1 0 136 137
G2 43 0 2 0 45 54 0 2 56
G3 2 19 8 0 29 0 7 42 49
G4 0 0 0 0 0 1 0 0 1
G8 97 4 5 1 107 1 0 0 1
G9 7 11 81 1 100 0 0 14 14
G10 0 0 6 0 6 0 0 0 0
G12 3 12 9 0 24 0 2 1 3
Total 160 59 392 3 614 57 9 195 261
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with clusters containing genotypes from all the three
study sites (Kibera, Lwak and Kilifi). However, three
post-vaccine strains (observed in 2015) clustered with
pre-vaccine strains, while one pre-vaccine strain (ob-
served in 2014) clustered within post-vaccine genotypes.
The strains in lineage III clustered with other strains iso-
lated from Kenya (2009), Togo (2011), Congo (2010),
Tanzania (2011), India (2011), USA (2011), Pakistan
(2010) and Kuwait (2016) showing nucleotide identities
ranging from 97 to 98%. The P [8]-I cluster contained a
single post-vaccine strain (KBR337), from Kibera, which
showed 100% nucleotide and amino acid identity to the
Rotarix vaccine and other vaccine-derived strains ob-
served in Vietnam and Japan. Lineage P [8]-IV cluster
contained strains observed in pre (2012 and 2014, from
Kibera and Lwak) and post (2018, from Kibera) vaccine
periods and clustered with isolates from Russia (2010).
Discussion
Prior to vaccine introduction, G1P [8] was the predom-
inant genotype. However, this genotype’s prevalence var-
ied substantially from year to year (dominant in 2011,
2013, 2014 and 2015; less so in 2010 and 2012), empha-
sizing the limits of short-term surveillance and the po-
tential for misrepresentation of patterns. During 2010
and 2012, a large proportion of children were infected
with genotype G8P [4], which was not detected in any
years following vaccination (except during 2017). Geno-
types G1P [8], G2P [4] and G9P [8] have also been iden-
tified as dominant genotypes in a study involving six
countries from Eastern and Southern Africa [7].
Genotype prevalence varied year to year and from be-
fore to after vaccine introduction. Interestingly, while
genotype G1P [8] showed no overall change in preva-
lence compared to the pre-vaccine period, it predomi-
nated only in the first year after vaccine introduction
(2015), and declined in prevalence thereafter, in particu-
lar to be replaced by G2P [4] in 2016, and by G3P [8] in
2018. Genotypes G8P [4] and G9P [8], which were the
second and third common genotypes in pre-vaccine
period, significantly declined in the post-vaccine period.
Predominance of G2P [4] and G3P [8] has been reported
worldwide following universal Rotarix vaccine introduc-
tion. For instance, G2P [4] was observed in Australia
[35] (in states using Rotarix) and Belgium [36] after vac-
cine introduction, while data from Ethiopia [37] and
Madagascar [38] depicted an increase in prevalence of
G3P [8] in post-vaccine introduction period. Studies on
the G3P [8] have revealed the emergence and spread of
strains of equine-like G3 genotype co-circulating with
wild-type G3 strains [39–41]. In here, 4.8% (2/41) were
detected to be of equine-like type (data not shown). Fur-
ther analysis on this genotype will illuminate of the gen-
etic diversity and prevalence of the emerging equine-like
in the post-vaccine introduction period. G2P [4] is one
of the genotypes of concern since this fully heterotypic
genotype has a different genomic constellation (DS-1-
like) to the genotype in the monovalent Rotarix vaccine
(Wa-like) [42]. There is no conclusive evidence associat-
ing the increase in prevalence of these genotypes to se-
lective vaccine pressure created by implementation of
Rotarix monovalent vaccine. Whilst the vaccine offers
Fig. 2 Comparison of prevalence of the dominant genotypes (G1P [8], G2P [4], G3P [8], G8P [4] and G9P [8]) at 95% confidence interval (CI)
during the pre- (Jan 2010-Jun 2014) and post-(July 2014 – Dec 2018) vaccine introduction periods in Kenya. The predominant genotypes were
selected based on their frequency as indicated in Table 3
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both homotypic and heterotypic protection [43, 44], the
emergence of the fully heterotypic G2P [4] and partially
heterotypic G3P [8] genotypes, and persistence in circu-
lation of the homotypic G1P [8] genotype after vaccine
introduction emphasizes the need for continued moni-
toring of impact of vaccine on genotypes.
We observed multiple uncommon G/P combinations
including G1P [4], G1P [6], G2P [8],G4P [4], G8P [8],
G8P [14], G10P [8], G12P [4] and G12P [6] at frequency
of < 2%. Genotype P [14] has been described sporadically
in humans and is believed to have originated from ani-
mal rotavirus and introduced into humans through in-
terspecies transmission and/or reassortment events [45].
The circulation of these uncommon genotypes demon-
strates the high diversity of RVA genotypes in Kenya
and concurs with findings from other African countries
[7]. However, genotype diversity was seen to decline in
post-vaccine period (only 11 GP combinations, com-
pared to 21 in pre-vaccine period), mirroring the experi-
ence of other countries, including Brazil and Zimbabwe,
Fig. 3 a Maximum likelihood phylogenetic tree of representative partial VP7 sequences (n = 180) of the G1 genotype that circulated in Kenya
between 2010 and 2018. Pre-vaccine Kenyan strains are marked as blue taxa, post-vaccine Kenyan strains are marked as red taxa while global
strains retrieved from GenBank are marked as black taxa. Only bootstrap values greater than or equal to 70 are shown. The scale bars indicate
nucleotide substitutions per site per year. b Maximum likelihood phylogenetic tree of representative partial VP4 sequences (n = 209) of the P [8]
genotype that circulated in Kenya between 2010 and 2018. Pre-vaccine Kenyan strains are marked as blue taxa, post-vaccine Kenyan strains are
marked as red taxa while global strains s retrieved from GenBank are marked as black taxa. Only bootstrap values greater than or equal to 70 are
shown. The scale bars indicate nucleotide substitutions per site per year
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which also indicated a decline in genotype variation after
vaccine introduction [46, 47]. This is in contrast to other
countries such Australia which observed increase in ge-
notypes after vaccine introduction [35]. Although diver-
sity seems to decrease following vaccine introduction, it
is unknown whether the observed trends will be sus-
tained in the long-term, especially in African settings
where pre-vaccine genotype diversity is high.
Phylogenetic analysis of genotype G1 revealed circula-
tion of strains of lineages G1-I and G1-II while the P [8]
strains formed three distinct clusters revealing circula-
tion of strains of lineages P [8]–I, P [8]-III and P [8]-IV.
The Kenyan strains were closely related to other global
strains as they segregated together. G1-I and P [8]-III
were the predominant lineages for both pre and post-
vaccine strains. These lineages were distinct from the
Rotarix vaccine lineages showing that the strains were
distantly related to the vaccine strain. Similar findings
were observed in data collected before and after vaccine
introduction in Eastern and Southern Africa countries
[7]. Although there were no lineage replacements after
vaccine introduction, the genetic diversity between pre
and post-vaccine strains, may suggest normal genetic
fluctuations or an effect of the vaccine. Interestingly, a
single case of vaccine-derived strain was observed in a
sample isolated from a child in Kibera, who had received
the first dose of the Rotarix vaccine. Phylogenetically,
the post-vaccine strain clustered with the Rotarix vac-
cine, in G1-I and P [8]-I lineages, and showed sequence
identities of 100% to the vaccine strain. These clusters
also contained previously vaccine-derived strains isolated
in Brazil, Korea, and Japan. Acute gastroenteritis, caused
by vaccine shedding or horizontal transmissions of the
vaccine strain have been reported at a higher rate in
other countries [48–50]. Further analysis will be neces-
sary to determine whether the observed vaccine strain
was as a result of vaccine shedding or horizontal trans-
mission event.
This study provides substantial epidemiological infor-
mation on changes in distribution and genetic diversity
of RVA genotypes in Kenya. Some limitations of this
study included fewer surveillance sites and unequal
distribution of the number of samples among the sites,
potentially underestimating the type of genotypes circu-
lating in the post-vaccine period. However, it is import-
ant to consider that there was an overall decline in
rotavirus circulation in the post-vaccine era, hence the
fewer specimens and less diversity could be a reflection
of less rotavirus circulation [14, 15]. Additionally, since
this is an ecological study, the changes in distribution
and diversity of genotypes in the post-vaccine era cannot
directly be attributed to vaccine introduction. Further-
more, due to unsuccessful sequencing and/or contig as-
sembly only two thirds of the total RVA positive samples
were fully genotyped. Lastly these findings may not be
generalized to the whole country because analysis was
based on rotavirus cases observed in health facilities in
three counties only.
Conclusion
In conclusion, we highlight the importance of monitor-
ing the transition in the prevalence of genotypes for a
better understanding of the performance of the currently
available vaccines. The emergence of the fully hetero-
typic G2P [4] and partially heterotypic G3P [8] geno-
types after vaccine introduction raises questions about
the epidemiological dynamics following vaccine intro-
duction. Previous analysis in Kenya showed that the vac-
cine had a significant impact on G1P [8] and non-
significant G2P [4] (although with limited statistical
power) [14], hence, continuous monitoring of the circu-
lating genotypes in the post-vaccine era is necessary.
Our findings also highlight existence of considerable
variation and genetic diversity within and between Ken-
yan pre and post-vaccine strains. One strain identified in
Kenya, was closely related to the Rotarix® vaccine strain,
likely representing shedding or horizontal transmission
of the vaccine strain. Additionally, continued surveil-
lance of the genetic characteristics of circulating RVA
strains is recommended to obtain a full view of the long-
term effects of vaccine introduction. Since immunity to
RVA involves immune responses conferred by genes
other than the commonly studied P and G genes, vac-
cine effectiveness might be challenged by changes occur-
ring on non-capsid genes. It is therefore recommended
that full genome analysis of genotypes collected in differ-
ent time or geographic regions be conducted to improve
understanding of their evolutionary profile during the
post-vaccine introduction period.
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